Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Evotec and X-Chem Enter Collaboration Agreement | Contract Pharma
Breaking News, Collaborations & Alliances

Evotec and X-Chem Enter Collaboration Agreement

Aim to accelerate early-stage drug discovery by combining Evotec’s screening platforms and capabilities with X-Chem’s DEL technology.

Evotec SE and X-Chem have entered a collaboration agreement focused on accelerating early-stage drug discovery.
 
X-Chem’s DNA-encoded library (DEL) technology streamlines hit finding by simultaneously screening up to billions of DNA-tagged compounds, thereby identifying potential start points with high efficiency and precision.
 
In partnership with Evotec’s screening platforms and capabilities, X-Chem is providing access to its DEL technology, including DELflex, a traditional experimental DEL solution, and HITMiner, a machine learning solution, leveraging high quality experimental DEL data to deliver optimal drug intervention starting points for innovative biological targets. 
 
“Partnerships to access best-in-class platforms are the way forward to address the complexity in drug discovery,” said Karen Lackey, CEO of X-Chem. “This collaboration highlights our commitment to partner with leading research organizations, like Evotec, to make DEL screening services more accessible.”
 
“We are pleased to collaborate with X-Chem and to leverage their leading DEL platform and capabilities,” said Craig Johnstone, chief operating officer of Evotec. “X-Chem’s expertise in DEL, combined with their advanced data-mining solutions, provides us with access to an additional tool to tackle innovative and difficult biological targets.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters